Genotypic Influences on Network Progression in Parkinson's Disease

Parkinson's disease (PD) patients with mutations in the glucocerebrosidase gene (GBA) tend to have a more aggressive disease course. GBA may therefore provide a target for disease modifying therapies in mutation carriers. Using positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging to measure network progression rates in mutation carriers will allow for the assessment of the potential disease modifying effects of new anti-GBA therapies.

The investigators will also determine whether magnetic resonance imaging (MRI) network methods, which are less invasive and more broadly available than positron emission tomography (PET), produce comparable network progression measurements in individual patients. These determinations will be critical for the design of clinical trials of new disease-modifying drugs.

Inclusion criteria

• Diagnosis of PD made according to United Kingdom (UK) Parkinson's Disease Society Brain Bank Criteria
• Ability to provide written informed consent
• Age 40-75
• Stable dose of antiparkinsonian medication for >1 month prior to study entry

Exclusion criteria

• Subjects with pathogenic mutations in LRRK2 related PD mutations (subjects with variants of uncertain significance (VUS) are eligible
• History of known causative factors such as encephalitis or neuroleptic treatment
• Patients with dementia (defined as Mini-Mental Status Exam score <24 or a Telephone Interview for Cognitive Status score <26)
• Atypical parkinsonian features including oculomotor abnormalities, incontinence, ataxia, sensory loss, or pyramidal signs
• Known structural brain lesions
• Patients with history of stroke, head injury, high intracranial pressure or severe headaches
• Psychiatric disorder, including a history of major depression in the past 36 months
• Pregnant or breastfeeding women (female subjects of child-bearing potential will be screened for pregnancy before imaging).